{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-038758","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.223013+00:00","generated_at":"2026-06-15T02:38:20.276195+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Longeveron Q1 loss $4.6M, cash $13.7M; CFO resigns; HLHS survival 100% at 5 yrs","bullets":["Net loss widened to $4.6M ($0.22/share) in Q1 2023 from $3.5M ($0.17/share) in Q1 2022.","Cash and marketable securities fell to $13.7M at March 31, 2023 from $19.6M at Dec 31, 2022.","CFO James Clavijo resigning effective June 9, 2023; external search for replacement ongoing.","ELPIS I HLHS trial shows 100% survival up to 5 years vs historical 20% mortality for Lomecel-B.","Topline results from CLEAR MIND Phase 2a Alzheimer's trial expected by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-038758","json":"https://secwatch.observer/filing/0001213900-23-038758.json","markdown":"https://secwatch.observer/filing/0001213900-23-038758.md","text":"https://secwatch.observer/filing/0001213900-23-038758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023038758/0001213900-23-038758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023038758/ea178436-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:38:20.276195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9fd34a74ba81959cc6a8a746461d7196dc47f7a7","claim":"Longeveron Inc. reported the first quarter ended March 31, 2023 results: revenue $0.3 million, net income $4.6 million, EPS $0.22.","evidence_excerpt":"Revenue for the first quarters of 2023 and 2022 was $0.3 million and $0.4 million, respectively. Revenue consisted of: ● Clinical trial revenue, which comes from our Bahamas Registry Trial, for the three months ended March 31, 2023, and 2022 was $0.2 million and $0.3 million, respectively, representing a 23% decline, despite demand increasing in the first quarter of 2023 versus first quarter 2022. The Company experienced some discounts and one-time price adjustments that reduced overall revenue in the first quarter of 2023 for the Bahamas Registry Trial. ● Grant revenue for each of the three months ended March 31, 2023, and 2022 was $0.1 million. R&D Expenses: Research and development expenses in the first quarter 2023 were $2.8 million compared to $1.4 million for the same period in 2022. The increase of $1.4 million, or 94%, was primarily due to an increase of $1.1 million in research and development expenses that were not reimbursable by grants. Equity-based compensation allocated t","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023038758/0001213900-23-038758-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$0.3 million"},{"label":"Net income","value":"$4.6 million"},{"label":"EPS","value":"$0.22"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}